GlassScriptPhysician profile
Michael A Rosenberg
NPI 1649859703
$1,381.56
in general payments reported to CMS, 2019-2025
17 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $402 · 2024: $669 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.73 | 2023-2025 | Lifevest |
| Medtronic, INC. | $187.54 | 2023-2025 | Corevalve Evolut R |
| Recor Medical INC | $171.23 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Janssen Pharmaceuticals, INC | $167.86 | 2023-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $109.74 | 2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $84.84 | 2023 | Ozempic |
| Philips North America LLC | $81.43 | 2023-2024 | (5044) Mcot, (Ck4) Mcot |
| Novartis Pharmaceuticals Corporation | $73.05 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $62.41 | 2023-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $39.01 | 2023 | Verquvo |
| Abiomed | $37.95 | 2025 | |
| Bard Peripheral Vascular, INC. | $35.19 | 2023 | Crosser Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.95 | 2024 | Jardiance |
| Amgen INC. | $24.49 | 2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $22.50 | 2024 | Arcalyst |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.25 | 2023 | |
| Boston Scientific Corporation | $16.39 | 2024 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.